Cadrenal gains FDA alignment on CAD-1005 trial
Compartilhar
Cadrenal Therapeutics (NASDAQ:CVKD) reported a positive outcome from a July 28, 2026 FDA Type D meeting regarding the planned Phase 3 registration study of CAD-1005 for heparin-induced thrombocytopenia.
